$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2013 Q3 Form 10-Q Financial Statement

#000119312513328105 Filed on August 09, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $9.000M $8.700M $20.90M
YoY Change -46.43% -58.37% 1.46%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.800M $5.800M $11.20M
YoY Change -46.88% -48.21% 33.33%
% of Gross Profit
Research & Development $34.46M $24.22M $21.72M
YoY Change 55.96% 11.47% -14.14%
% of Gross Profit
Depreciation & Amortization $2.800M $2.700M $2.600M
YoY Change 21.74% 3.85% 100.0%
% of Gross Profit
Operating Expenses $41.23M $30.00M $32.95M
YoY Change 18.1% -8.96% -2.32%
Operating Profit -$32.23M -$21.31M -$12.07M
YoY Change 77.63% 76.61%
Interest Expense $300.0K $300.0K -$900.0K
YoY Change -121.43% -133.33% 28.57%
% of Operating Profit
Other Income/Expense, Net $278.0K $259.0K -$889.0K
YoY Change -120.52% -129.13%
Pretax Income -$31.96M -$21.05M -$12.96M
YoY Change 63.86% 62.5% -6.12%
Income Tax -$2.270M -$2.884M $0.00
% Of Pretax Income
Net Earnings -$29.69M -$18.17M -$12.96M
YoY Change 52.22% 40.24% -6.28%
Net Earnings / Revenue -329.84% -208.84% -61.99%
Basic Earnings Per Share
Diluted Earnings Per Share -$476.0K -$295.0K -$253.4K
COMMON SHARES
Basic Shares Outstanding 62.96M shares 62.17M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $193.8M $209.7M $229.0M
YoY Change -15.13% -8.43% 5.09%
Cash & Equivalents $11.84M $24.98M $48.27M
Short-Term Investments $181.9M $184.7M $180.8M
Other Short-Term Assets $4.800M $4.200M $6.900M
YoY Change -15.79% -39.13% 35.29%
Inventory
Prepaid Expenses
Receivables $600.0K $500.0K $4.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $199.2M $214.4M $240.3M
YoY Change -15.58% -10.8% 7.13%
LONG-TERM ASSETS
Property, Plant & Equipment $16.97M $18.05M $14.20M
YoY Change -9.67% 27.08% -12.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $231.4M $230.2M $63.70M
YoY Change -8499.27% 261.38% -36.24%
Other Assets
YoY Change
Total Long-Term Assets $248.3M $248.2M $78.20M
YoY Change 187.37% 217.39% -32.88%
TOTAL ASSETS
Total Short-Term Assets $199.2M $214.4M $240.3M
Total Long-Term Assets $248.3M $248.2M $78.20M
Total Assets $447.5M $462.6M $318.5M
YoY Change 38.82% 45.23% -6.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.728M $4.534M $5.500M
YoY Change -46.44% -17.56% -30.38%
Accrued Expenses $15.39M $8.488M $14.20M
YoY Change 3.16% -40.23% 24.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.90M $53.07M $57.10M
YoY Change 0.25% -7.06% -43.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $95.00M $101.3M $73.10M
YoY Change 18134.17% 38.58% -29.51%
Total Long-Term Liabilities $95.00M $101.3M $73.10M
YoY Change 18134.17% 38.58% -29.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.90M $53.07M $57.10M
Total Long-Term Liabilities $95.00M $101.3M $73.10M
Total Liabilities $149.9M $154.4M $130.2M
YoY Change 3.26% 18.57% -36.27%
SHAREHOLDERS EQUITY
Retained Earnings -$563.9M -$534.2M
YoY Change 26.76%
Common Stock $834.3M $814.2M
YoY Change 34.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $297.6M $308.2M $188.3M
YoY Change
Total Liabilities & Shareholders Equity $447.5M $462.6M $318.5M
YoY Change 38.82% 45.23% -6.54%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$29.69M -$18.17M -$12.96M
YoY Change 52.22% 40.24% -6.28%
Depreciation, Depletion And Amortization $2.800M $2.700M $2.600M
YoY Change 21.74% 3.85% 100.0%
Cash From Operating Activities -$21.70M -$23.60M -$21.70M
YoY Change -517.31% 8.76% -18.42%
INVESTING ACTIVITIES
Capital Expenditures -$900.0K -$400.0K -$1.600M
YoY Change -84.48% -75.0% 220.0%
Acquisitions
YoY Change
Other Investing Activities -$1.500M -$52.90M $9.200M
YoY Change -106.36% -675.0% 196.77%
Cash From Investing Activities -$2.600M -$53.20M $7.600M
YoY Change -114.53% -800.0% 192.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.10M 4.000M 600.0K
YoY Change 146.67% 566.67% 20.0%
NET CHANGE
Cash From Operating Activities -21.70M -23.60M -21.70M
Cash From Investing Activities -2.600M -53.20M 7.600M
Cash From Financing Activities 11.10M 4.000M 600.0K
Net Change In Cash -13.20M -72.80M -13.50M
YoY Change -147.83% 439.26% -42.55%
FREE CASH FLOW
Cash From Operating Activities -$21.70M -$23.60M -$21.70M
Capital Expenditures -$900.0K -$400.0K -$1.600M
Free Cash Flow -$20.80M -$23.20M -$20.10M
YoY Change -289.09% 15.42% -22.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 us-gaap Share Price
SharePrice
20.13
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62960006 shares
CY2012Q1 us-gaap Share Price
SharePrice
10.75
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48274000
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62457513 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62457513 shares
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
97636000
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
53066000
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28130000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4534000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
308175000
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
813613000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-534192000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33560000
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8488000
CY2013Q2 us-gaap Liabilities
Liabilities
154383000
CY2013Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3681000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
624000
CY2013Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1252000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462558000
CY2013Q2 us-gaap Available For Sale Securities Equity Securities Noncurrent
AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
60336000
CY2013Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
184719000
CY2013Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
169818000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18045000
CY2013Q2 us-gaap Assets
Assets
462558000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24975000
CY2013Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
355045000
CY2013Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
354537000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4205000
CY2013Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
460000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
214359000
CY2013Q2 alny Accrued Intraperiod Tax Allocation
AccruedIntraperiodTaxAllocation
5232000
CY2013Q2 alny Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
523000
CY2013Q2 alny Availableforsale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
15000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70228000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52489936 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Liabilities
Liabilities
153467000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52489936 shares
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
100874000
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
48345000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15662000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4420000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
134053000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
624876000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-507010000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
31417000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11558000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4248000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
525000
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
950000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287520000
CY2012Q4 us-gaap Available For Sale Securities Equity Securities Noncurrent
AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
38748000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
71407000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
103416000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19799000
CY2012Q4 us-gaap Assets
Assets
287520000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51405000
CY2012Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
174889000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
174823000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2641000
CY2012Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
104000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
125557000
CY2012Q4 alny Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
97000
CY2012Q4 alny Availableforsale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
31000
dei Trading Symbol
TradingSymbol
ALNY
dei Entity Registrant Name
EntityRegistrantName
ALNYLAM PHARMACEUTICALS, INC.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001178670
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14714000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60424000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24573000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9171000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect&#xA0;the reported amounts of assets and liabilities and&#xA0;the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and&#xA0;the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
us-gaap Investment Income Net
InvestmentIncomeNet
494000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1650000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2178000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
27329000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12468000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30628000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
274428000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-192000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
356000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31116000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
488000
us-gaap Net Income Loss
NetIncomeLoss
-27182000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3043000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12051000
us-gaap Restricted Stock Expense
RestrictedStockExpense
1300000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
182192000
us-gaap Share Based Compensation
ShareBasedCompensation
6452000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-26430000
us-gaap Operating Expenses
OperatingExpenses
58445000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3446000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1095000
us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-3446000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
470000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
173572000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4838000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
92557000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-184049000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46394000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8620000
alny Non Cash Stock Based Compensation Expenses Research And Development
NonCashStockBasedCompensationExpensesResearchAndDevelopment
4287000
alny Non Cash Stock Based Compensation Expenses General And Administrative
NonCashStockBasedCompensationExpensesGeneralAndAdministrative
2165000
alny Short Term Investment Maturity Period Minimum
ShortTermInvestmentMaturityPeriodMinimum
P90D
alny Charge For Four Zero One K Company Stock Match
ChargeForFourZeroOneKCompanyStockMatch
247000
alny Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P90D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48877000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51909000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9236000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2028000
us-gaap Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
179000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1933000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
162000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
41471000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
103000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24324000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
157104000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
170000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
328000
us-gaap Investment Income Net
InvestmentIncomeNet
494000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2613000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24221000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22960000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21634000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2587000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2917000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1364000
us-gaap Net Income Loss
NetIncomeLoss
-24324000
us-gaap Restricted Stock Expense
RestrictedStockExpense
1200000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
87947000
us-gaap Share Based Compensation
ShareBasedCompensation
6252000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21954000
us-gaap Operating Expenses
OperatingExpenses
64431000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-37400000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-281000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
86800000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4726000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
101207000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57992000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42797000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1475000
alny Non Cash Stock Based Compensation Expenses Research And Development
NonCashStockBasedCompensationExpensesResearchAndDevelopment
4086000
alny Non Cash Stock Based Compensation Expenses General And Administrative
NonCashStockBasedCompensationExpensesGeneralAndAdministrative
2166000
alny Charge For Four Zero One K Company Stock Match
ChargeForFourZeroOneKCompanyStockMatch
212000
CY2012Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8625000 shares
CY2012Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
86800000
CY2012Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5900000
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9200000 shares
CY2013Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
173600000
CY2013Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
11600000
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51280000 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9236000 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2012Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1139000
CY2012Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
20884000
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-25000
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12956000
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21000
CY2012Q2 us-gaap Investment Income Net
InvestmentIncomeNet
271000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12981000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12067000
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-889000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-12956000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11228000
CY2012Q2 us-gaap Restricted Stock Expense
RestrictedStockExpense
700000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
32951000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21723000
CY2012Q2 alny Non Cash Stock Based Compensation Expenses Research And Development
NonCashStockBasedCompensationExpensesResearchAndDevelopment
1998000
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9171000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61661000 shares
CY2012Q2 alny Non Cash Stock Based Compensation Expenses General And Administrative
NonCashStockBasedCompensationExpensesGeneralAndAdministrative
1098000
CY2013Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
8687000
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7309000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21053000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2013Q2 us-gaap Investment Income Net
InvestmentIncomeNet
270000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10860000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21312000
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
259000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-18169000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5784000
CY2013Q2 us-gaap Restricted Stock Expense
RestrictedStockExpense
600000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
29999000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2884000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24215000
CY2013Q2 alny Non Cash Stock Based Compensation Expenses Research And Development
NonCashStockBasedCompensationExpensesResearchAndDevelopment
2200000
CY2013Q2 alny Non Cash Stock Based Compensation Expenses General And Administrative
NonCashStockBasedCompensationExpensesGeneralAndAdministrative
1177000

Files In Submission

Name View Source Status
0001193125-13-328105-index-headers.html Edgar Link pending
0001193125-13-328105-index.html Edgar Link pending
0001193125-13-328105.txt Edgar Link pending
0001193125-13-328105-xbrl.zip Edgar Link pending
alny-20130630.xml Edgar Link completed
alny-20130630.xsd Edgar Link pending
alny-20130630_cal.xml Edgar Link unprocessable
alny-20130630_def.xml Edgar Link unprocessable
alny-20130630_lab.xml Edgar Link unprocessable
alny-20130630_pre.xml Edgar Link unprocessable
d558254d10q.htm Edgar Link pending
d558254dex101.htm Edgar Link pending
d558254dex12.htm Edgar Link pending
d558254dex311.htm Edgar Link pending
d558254dex312.htm Edgar Link pending
d558254dex321.htm Edgar Link pending
d558254dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending